S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:FULC

Fulcrum Therapeutics - FULC Stock Forecast, Price & News

$6.14
-0.11 (-1.76%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.06
$6.43
50-Day Range
$5.01
$8.35
52-Week Range
$3.21
$24.79
Volume
181,726 shs
Average Volume
561,507 shs
Market Capitalization
$319.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.71

Fulcrum Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
269.9% Upside
$22.71 Price Target
Short Interest
Bearish
6.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Fulcrum Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.45) to ($2.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

440th out of 1,027 stocks

Pharmaceutical Preparations Industry

193rd out of 503 stocks

FULC stock logo

About Fulcrum Therapeutics (NASDAQ:FULC) Stock

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FULC Stock News Headlines

FULC, CMBM: 2 Underdog Stocks That Deserve Attention Right Now
SVB Securities Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics Earnings Preview
See More Headlines
Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FULC Company Calendar

Last Earnings
11/04/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/02/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FULC
Fax
N/A
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.71
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+269.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-80,850,000.00
Net Margins
-1,000.65%
Pretax Margin
-1,000.65%

Debt

Sales & Book Value

Annual Sales
$19.16 million
Book Value
$5.22 per share

Miscellaneous

Free Float
44,504,000
Market Cap
$319.59 million
Optionable
Not Optionable
Beta
1.96

Key Executives

  • Mr. Bryan E. Stuart (Age 46)
    Pres, CEO & Director
    Comp: $836.38k
  • Dr. Judith A. Dunn Ph.D. (Age 60)
    Interim Chief Medical Officer
    Comp: $665.89k
  • Dr. Bradley E. Bernstein M.D.
    Ph.D., Founder
  • Dr. Michael R. Green
    Founder
  • Dr. Rudolf Jaenisch M.D.
    Ph.D., Founder
  • Prof. Jeannie T. Lee M.D.
    Ph.D., Founder
  • Dr. Danny Reinberg
    Founder
  • Ms. Esther P. Rajavelu (Age 43)
    CFO & Treasurer
  • Mr. Mel Hayes (Age 52)
    Chief Operating Officer
  • Mr. Gregory Tourangeau
    Controller & Principal Accounting Officer













FULC Stock - Frequently Asked Questions

Should I buy or sell Fulcrum Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FULC shares.
View FULC analyst ratings
or view top-rated stocks.

What is Fulcrum Therapeutics' stock price forecast for 2023?

7 equities research analysts have issued 12 month price targets for Fulcrum Therapeutics' stock. Their FULC share price forecasts range from $11.00 to $35.00. On average, they predict the company's share price to reach $22.71 in the next twelve months. This suggests a possible upside of 269.9% from the stock's current price.
View analysts price targets for FULC
or view top-rated stocks among Wall Street analysts.

How have FULC shares performed in 2022?

Fulcrum Therapeutics' stock was trading at $17.69 on January 1st, 2022. Since then, FULC shares have decreased by 65.3% and is now trading at $6.14.
View the best growth stocks for 2022 here
.

When is Fulcrum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our FULC earnings forecast
.

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.57) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.07. The company had revenue of $4.94 million for the quarter, compared to the consensus estimate of $2.94 million. Fulcrum Therapeutics had a negative net margin of 1,000.65% and a negative trailing twelve-month return on equity of 54.55%. During the same quarter in the previous year, the business posted ($0.70) EPS.

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).

When did Fulcrum Therapeutics IPO?

(FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO.

What is Fulcrum Therapeutics' stock symbol?

Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC."

Who are Fulcrum Therapeutics' major shareholders?

Fulcrum Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (13.45%), RTW Investments LP (7.66%), BlackRock Inc. (5.33%), Vanguard Group Inc. (3.76%), Point72 Asset Management L.P. (2.87%) and VR Adviser LLC (2.31%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Diego Cadavid, James A Geraghty, Owen B Wallace, Peter G Thomson, Peter G Thomson, Robert J Gould and Robert J Gould.
View institutional ownership trends
.

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulcrum Therapeutics' stock price today?

One share of FULC stock can currently be purchased for approximately $6.14.

How much money does Fulcrum Therapeutics make?

Fulcrum Therapeutics (NASDAQ:FULC) has a market capitalization of $319.59 million and generates $19.16 million in revenue each year. The company earns $-80,850,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does Fulcrum Therapeutics have?

The company employs 104 workers across the globe.

How can I contact Fulcrum Therapeutics?

Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.fulcrumtx.com. The company can be reached via phone at (617) 651-8851 or via email at christina.tartaglia@sternir.com.

This page (NASDAQ:FULC) was last updated on 12/8/2022 by MarketBeat.com Staff